Liposomal amphotericin B

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A 28-year-old woman developed a fungal infection called histoplasmosis after having a tooth extracted, with the infection spreading to her lungs and sinuses. She was initially given a common antifungal medication called itraconazole, but her condition continued to worsen despite increasing the dose. When doctors switched her to a stronger medication called liposomal amphotericin B given intravenously, she improved dramatically and recovered fully. This case shows the importance of recognizing when a standard fungal treatment is not working and switching to more aggressive therapy.

Fungal Pneumonia and Severe Neutropenia: Risk Factors for Increased 90 Day Mortality

mycolabadmin

This study examined 39 cancer patients with severe fungal lung infections treated at a major cancer center. Patients who received antifungal treatment within 7 days and started with a specific drug called liposomal amphotericin B had better survival rates at 90 days. The research suggests that quick diagnosis and prompt treatment initiation are critical for improving survival in immunocompromised patients with fungal pneumonia.

Brazilian task force for the management of mucormycosis

mycolabadmin

Mucormycosis is a serious fungal infection that has become more common in Brazil, especially during COVID-19. This medical emergency requires rapid diagnosis through imaging and tissue sampling, combined with aggressive treatment including antifungal medications and surgery to remove infected tissue. The Brazilian government has made these powerful antifungal drugs more available to improve patient survival and reduce the severe complications of this dangerous infection.

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

mycolabadmin

This study tested a new antifungal drug called SF001 against a serious infection called fusariosis in mice. SF001 performed as well as the current standard treatment (amphotericin B) but with better safety profiles. The drug successfully reduced fungal infections in organs and improved survival rates in infected mice without showing signs of toxicity at higher doses.

Pulmonary Mucormycosis in Diabetic Patients: A Case Series From a Tertiary Respiratory Center in Sri Lanka

mycolabadmin

This case study describes three diabetic patients in Sri Lanka who developed a serious lung infection caused by a fungus called mucormycosis. The infection caused cavities in the lungs and symptoms like fever, cough, and weight loss. Two patients recovered with antifungal medication (amphotericin B) and surgery, while one patient sadly died despite receiving treatment. The study emphasizes that doctors should consider this infection in diabetic patients with unusual lung symptoms to catch it early.

Cutaneous Mucormycosis Following Polytrauma: A Multidisciplinary Approach

mycolabadmin

A 22-year-old man suffered severe injuries from a motorcycle-truck collision that damaged his perineal area and left thigh. Despite antibiotics and wound therapy, a dangerous fungal infection called mucormycosis developed in the wound. The medical team treated this by repeatedly removing infected tissue, using powerful antifungal medications (amphotericin B and posaconazole), and carefully managing the wound with special therapy before skin grafting, ultimately achieving successful healing.

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A healthy 28-year-old woman developed a serious fungal infection caused by Histoplasma capsulatum after dental surgery. The standard antifungal medication (itraconazole) did not work for her, even at high doses. Doctors successfully treated her with a more powerful antifungal drug called liposomal amphotericin B, which cleared the infection completely. This case shows the importance of adjusting treatment when patients don’t respond to initial therapy.

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A 28-year-old woman developed a serious fungal infection (histoplasmosis) after dental surgery that was initially misdiagnosed as a bacterial infection. Although she was treated with an antifungal medication called itraconazole, her condition worsened with larger lung lesions appearing. When switched to a stronger intravenous antifungal called liposomal amphotericin B, she rapidly improved and fully recovered, demonstrating the importance of adjusting treatment when patients don’t respond as expected.

Disseminated histoplasmosis with bone marrow infiltration in a newly diagnosed HIV patient

mycolabadmin

A Colombian patient living in Spain developed a serious fungal infection (histoplasmosis) that spread throughout his body and affected his bone marrow, which was discovered during his HIV diagnosis. Doctors identified the infection by examining bone marrow cells under a microscope and confirmed it with fungal culture and genetic testing. The patient was treated with antifungal medication (liposomal amphotericin B) along with HIV medications and recovered well, highlighting the importance of bone marrow testing in severely immunocompromised HIV patients.

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

mycolabadmin

This review examined how well liposomal amphotericin B (a fungal medication) works to prevent serious fungal infections in children. Researchers looked at 20 studies involving over 2000 children and found that about 7% still developed fungal infections despite the medication, with common side effects being low potassium levels and liver problems. The main finding is that doctors use this medication in very different ways, and we need better research to figure out the best dosing strategy for children.

Research Keyword: Liposomal amphotericin B